Teprotumumab-Related Hyperglycemia
The Journal of Clinical Endocrinology & Metabolism · 10.03.2023 · 108 (4) · 858-864
DOI: 10.1210/clinem/dgac627 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 27.10.2022. Verfasst von Linus Amarikwa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA 94304, USA. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Prediabetic State, Hyperglycemia. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Context
Graves orbitopathy (GO) or thyroid eye disease is a potentially sight-threatening and disfiguring autoimmune disease. Teprotumumab is a monoclonal antibody against the insulin-like growth factor-I receptor that was recently approved for GO treatment. Hyperglycemia is a recognized adverse event of teprotumumab, occurring in 10% of patients in 2 recent randomized controlled trials.
Objective
Our study aimed to report the incidence, severity, management, and longitudinal glycemic changes in patients treated with teprotumumab in an academic practice cohort.
Methods
This longitudinal, observational study included all consecutive patients treated with teprotumumab between March 2020 and May 2022 at 1 institution. Hemoglobin A1c (HbA1c) was measured every 3 months.
Results
Forty-two patients with baseline normoglycemia (n = 22), prediabetes (n = 10), and diabetes (n = 10) were followed for a mean of 47.5 weeks. Overall, HbA1c increased by 0.5% at 3 months. Least-squares mean changes in HbA1c at 3 months were 1.3 (P < .001), 0.7 (P = .01), and 0.1 (P = .41) in patients with diabetes, prediabetes, and normoglycemia, respectively. Twenty-two patients (52%) had hyperglycemia, which was graded as mild, moderate, and life-threatening in 55% (12/22), 41% (9/22), and 5% (1/22) of cases, respectively. Age, pre-existing diabetes, and Hispanic and Asian race/ethnicity were significant risk factors for hyperglycemia. Among patients with hyperglycemia, 36.4% (8/22) returned to baseline glycemic status at last follow-up.
Conclusion
While effective, teprotumumab carries a significant risk of hyperglycemia, especially in patients with diabetes. Hyperglycemia may persist after stopping teprotumumab. These findings underscore the importance of guidelines for screening and management of teprotumumab-related hyperglycemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA 94304, USA.
- Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
- Stanford Diabetes Research Center, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
ORCID-Profile: Linus Amarikwa, Abubakr Mohamed, Sun H Kim, Andrea Lora Kossler, Chrysoula Dosiou
Förderung
- NEI NIH HHS
- National Institute of Health
Zitieren
APA
Amarikwa, L., Mohamed, A., Kim, S. H., Kossler, A. L., & Dosiou, C. (2023). Teprotumumab-Related Hyperglycemia. The Journal of Clinical Endocrinology & Metabolism, 108(4), 858-864. https://doi.org/10.1210/clinem/dgac627
Vancouver
Amarikwa L, Mohamed A, Kim SH, Kossler AL, Dosiou C. Teprotumumab-Related Hyperglycemia. The Journal of Clinical Endocrinology & Metabolism. 2023;108(4):858-864. doi:10.1210/clinem/dgac627
BibTeX
@article{Amarikwa2023,
author = {Amarikwa, Linus and Mohamed, Abubakr and Kim, Sun H and Kossler, Andrea Lora and Dosiou, Chrysoula},
title = {Teprotumumab-Related Hyperglycemia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {4},
pages = {858--864},
doi = {10.1210/clinem/dgac627}
}
EUVIMED